1. Introduction Bitespiramycin, a new 16-membered macrolide antibiotic, has been shown to have excellent therapeutic effect against respiratory tract inflammation, including the potential effect against COVID-19 [1]. It has been listed in a clinical trial (ClinicalTrials.gov Identifier: NCT04672564) to validate the efficacy against COVID-19 by National Institutes of Health (NIH) [2].
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile